We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

109 hedge funds and large institutions have $793M invested in Coherus Oncology in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 25

25% more call options, than puts

Call options by funds: $6.08M | Put options by funds: $4.85M

4.78% more ownership

Funds ownership: 68.52% → 73.3% (+4.8%)

6% less capital invested

Capital invested by funds: $842M → $793M (-$49M)

11% less funds holding

Funds holding: 122 → 109 (-13)

16% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 25

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
109
Holders Change
-13
Holders Change %
-10.66%
% of All Funds
2.71%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
21
Increased
50
Reduced
25
Closed
25
Calls
$6.08M
Puts
$4.85M
Net Calls
+$1.23M
Net Calls Change
+$4.26M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$69.9M
2
PHS
PFM Health Sciences
California
+$36.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$27.7M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$25.6M
5
CC
Carlson Capital
Texas
+$19.8M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16.9M
2
Two Sigma Investments
Two Sigma Investments
New York
-$3.25M
3
Morgan Stanley
Morgan Stanley
New York
-$2.12M
4
LOAMS
Lombard Odier Asset Management (Switzerland)
Switzerland
-$2.11M
5
AC
Ascend Capital
California
-$1.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
BM
26
Bridger Management
New York
$6.97M – – –
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$6.76M +$4.5M +183,012 +134%
CS
28
Candriam SCA
Luxembourg
$6.09M +$541K +22,000 +8%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$5.77M +$840K +34,139 +14%
Lord, Abbett & Co
30
Lord, Abbett & Co
New Jersey
$4.85M -$816K -33,162 -13%
CCI
31
Columbus Circle Investors
$4.72M +$290K +11,792 +6%
TA
32
Teachers Advisors
New York
$4.65M +$1.77M +71,918 +49%
CWG
33
C WorldWide Group
Denmark
$4.08M +$2.42M +98,211 +104%
Allianz Asset Management
34
Allianz Asset Management
Germany
$3.98M +$668K +27,140 +17%
BG
35
Bellevue Group
Switzerland
$3.7M – – –
Bank of New York Mellon
36
Bank of New York Mellon
New York
$3.49M +$618K +25,108 +18%
CS
37
Credit Suisse
Switzerland
$3.47M +$540K +21,958 +15%
EAM
38
Eventide Asset Management
Massachusetts
$3.07M – – –
Citadel Advisors
39
Citadel Advisors
Florida
$3.06M -$1.6M -64,945 -31%
Goldman Sachs
40
Goldman Sachs
New York
$2.98M +$2.45M +99,548 +240%
Principal Financial Group
41
Principal Financial Group
Iowa
$2.93M +$3.41M +138,440 New
Charles Schwab
42
Charles Schwab
California
$2.84M +$365K +14,838 +12%
SIM
43
Spark Investment Management
New York
$2.64M +$2.57M +104,300 +506%
KCM
44
Kennedy Capital Management
Missouri
$2.6M +$2.36K +96 +0.1%
Renaissance Technologies
45
Renaissance Technologies
New York
$2.39M +$2.78M +113,200 New
RPAM
46
Rhenman & Partners Asset Management
Sweden
$2.35M – – –
VMI
47
VHCP Management II
New York
$2.02M -$845K -34,353 -27%
SM
48
Sabby Management
Florida
$1.97M +$1.59M +64,690 +226%
TCM
49
Tekla Capital Management
Massachusetts
$1.9M – – –
Deutsche Bank
50
Deutsche Bank
Germany
$1.43M -$809K -32,868 -33%
1
2
3 4 5

CHRS Hedge Fund Activity: Q1 2017 in Review

109 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2017, worth a combined $793M — down 5.8% from $842M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of CHRS and 21 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 50 added.

The largest buyer was BlackRock, adding an estimated $69.9M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $16.9M sold.

  • 109 institutional investors held Coherus Oncology (CHRS) as of Q1 2017, down from 122 in Q4 2016.
  • Funds reported $793M of Coherus Oncology stock for Q1 2017, down 5.8% quarter-over-quarter.
  • 21 funds opened new Coherus Oncology positions in Q1 2017 and 25 closed out, a net change of -4 holders.
  • The largest Coherus Oncology buyer in Q1 2017 was BlackRock, an estimated $69.9M added.
  • The largest Coherus Oncology seller in Q1 2017 was Point72 Asset Management, an estimated $16.9M sold.

Based on aggregated 13F filings for Q1 2017.